Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000116.xml
Download PDF
Semin Vasc Med 2002; 2(2): 127-138
DOI: 10.1055/s-2002-32036
DOI: 10.1055/s-2002-32036
Treating High Blood Pressure in Diabetes: The Evidence
Further Information
Publication History
Publication Date:
06 June 2002 (online)
ABSTRACT
Increases in blood pressure, even at modest levels, are associated with an increased risk of complications in diabetes. Trials have shown that treatment with blood pressure-lowering agents in type 2 diabetes lowers the risk of complications of cardiovascular and microvascular complications. ACE inhibitors appear superior in patients with microalbuminuria, although the choice of other agents is less clear, making blood pressure control itself more important than the particular agent used. The probability that a patient will require multiple therapies is increased in patients with diabetes, in part because of the increased likelihood of concurrent cardiovascular illness for which antihypertensives may have benefit. Finally, some drugs used to lower blood pressure have a benefit in individuals not considered hypertensive and appear to have a mechanism of action independent of blood pressure lowering.
KEYWORDS
Diabetes - ACE inhibitors - calcium channel blockers - diuretics - blood-pressure lowering
REFERENCES
- 1 Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet . 2000; 356 1955-1963
- 2 Furberg C. Hypertension and diabetes: current issues. Am Heart J . 1999; 138 S400-S405
- 3 Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet . 1995; 346 1647-1653
- 4 MacMahon S, Peto R, Cutler J. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet . 1990; 335 765-774
- 5 Stamler J, Vaccaro O, Neaton J D, Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care . 1993; 16 434-444
- 6 Hanefeld M, Fischer S, Julius U. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia . 1996; 39 1577-1583
- 7 Kuusisto J, Mykkanen L, Pyorala K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes . 1994; 43 960-967
- 8 Lehto S, Ronnemaa T, Haffner S, Pyorala K, Kallio V, Laakso M. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes . 1997; 48 1354-1359
- 9 Wei M, Gaskill S P, Haffner S M, Stern M P. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. Diabetes Care . 1998; 21 1167-1172
- 10 Gall M-A, Borch-Johnsen K, Hougaard P, Nielsen F S, Parving H-H. Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes . 1995; 44 1303-1309
- 11 Adler A T, Stratton I M, Neil M A. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36). BMJ . 2000; 321 412-419
- 12 Heart Outcome Prevention Evaluation Study Investigators. Effect of an angiotensin-converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction and stroke in high-risk patients. N Engl J Med . 2000; 342 145-160
- 13 Estacio R O, Jeffers B W, Hiatt W R, Biggerstaff S L, Gifford N, Schrier R W. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med . 1998; 338 645-652
- 14 Estacio R, Jeffers B, Gifford N, Schrier R. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care . 2000; B54-B64 (B54-B64)
- 15 Hansson L, Zanchetti A, Carruthers S G. Effect of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet . 1998; 351 1755-1762
- 16 Curb J D, Pressel S L, Cutler J A. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA . 1996; 276 1886-1892
- 17 Staessen J A, Fagard R R, Thijs L. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet . 1997; 350 757-764
- 18 Tuomilehto J, Rastenyte D, Birkenhäger W H. Effect of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med . 1999; 340 677-684
- 19 Wang J, Staessen J, Gong L, Liu L. Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Intern Med . 2000; 160 211-220
- 20 United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ . 1998; 317 703-713
- 21 Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet . 2000; 355 253-259
- 22 Schrier R, Estacio R. Additional follow-up from the ABCD trial in patients with type 2 diabetes and hypertension. N Engl J Med . 2000; 343 1969
- 23 Hansson L, Lindholm L, Niskanen L. Effect of angiotensin converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet . 1999; 353 611-616
- 24 Puddey I B. Large multicentre hypertension trials. Curr Opin Nephrol Hypertens . 2000; 9 285-292
- 25 Tatti P, Pahor M, Byington R. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care . 1998; 21 597-603
- 26 Hansson L, Hedner T, Lund-Johansen P. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet . 2000; 356 359-365
- 27 Hansson L, Lindholm L, Ekbom T. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet . 1999; 354 1751-1756
- 28 Lindholm L, Hansson L, Ekbom T. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. J Hypertens . 2000; 18 1671-1675
- 29 UKPDS Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 39). BMJ . 1998; 317 713-720
- 30 Joint National Committee on Prevention, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med . 1997; 157 2413-2444
- 31 Bourgault C, Rainville B, Suissa S. Antihypertensive drug therapy in Saskatchewan: patterns of use and determinants in hypertension. Arch Intern Med . 2001; 161 1873-1879
- 32 Ridao N, Luno J, Garcia de Vinuesa S, Gomez F, Tejedor A, Valderrabano F. Prevalence of hypertension in renal disease. Nephrol Dial Transplant . 2001; 70-73 (70-73)
- 33 Paauw D. Did we learn evidence-based medicine in medical school?. <~>Some common medical mythology. J Am Board Fam Pract . 1999; 12 143-149
- 34 Chalon S, Berlin I, Sachon C, Bosquet F, Grimaldi A. Propranolol in hypoglycaemia unawareness. Diabete Metab . 1999; 25 23-26
- 35 Shorr R, Ray W, Daugherty J, Griffin M. Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA . 1997; 278 40-43
- 36 Harper R, Ennis C, Heaney A. A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM. Diabetologia . 1995; 38 853-859
- 37 Janka H, Holreve H, Nakov R. Comparison of the effect of an ACE inhibitor/calcium antagonist and a beta-blocker/diuretic combination on glycemic control in type 2 diabetic patients with hypertension: The AC-VT study. Diabetes . 2000; A18-A19 (A18-A19)
- 38 Haffner S. Metabolic predictors of hypertension. J Hypertens . 1999; 17 S23-S28
- 39 ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA . 2000; 283 1967-1975
- 40 Fuller J, Stevens L, Chaturvedi N, Holloway J. Antihypertensive therapy for preventing cardiovascular complications in people with diabetes mellitus. Cochrane Database Syst Rev 2000;CD 002188.
- 41 Lievre M, Gueyffier F, Ekbom T. Efficacy of diuretics and beta-blockers in diabetic hypertensive patients. Results from a meta-analysis. The INDANA Steering Committee. Diabetes Care . 2000; B65-B71 (B65-B71)
- 42 Pahor M, Psaty B, Alderman M, Applegate W, Williamson J, Furberg C. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care . 2000; 23 888-892
- 43 Gerstein H, Mann J, Yi Q. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA . 2001; 286 421-426
- 44 Almdal T, Norgaard K, Feldt-Rasmussen B, Deckert T. The predictive value of microalbuminuria in IDDM. A five-year follow-up study. Diabetes Care . 1994; 17 120-125
- 45 Brancati F, Cusumano A. Epidemiology and prevention of diabetic nephropathy. Curr Opin Nephrol Hypertens . 1995; 4 223-229
- 46 Lewis E J, Hunsicker L G, Bain R P, Rohde R D. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med . 1993; 329 1456-1462
- 47 Hebert L, Bain R, Verme D. Remission of nephrotic range proteinuria in type I diabetes. Collaborative Study Group. Kidney Int . 1994; 46 1688-1693
- 48 Voyaki S, Staessen J, Thijs L. Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. J Hypertens . 2001; 19 511-519
- 49 Tarnow L, Rossing P, Jensen C, Hansen B, Parving H. Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy. Diabetes Care . 2000; 23 1723-1730
- 50 The Microalbuminuria Captopril Study Group. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia . 1996; 39 587-593
- 51 Viberti G, Mogensen C E, Groop L C, Pauls J F. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA . 1994; 271 275-279
- 52 Laffel L, McGill J, Gans D. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Am J Med . 1995; 99 497-504
- 53 Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet . 1997; 349 1787-1792
- 54 The ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. . Ann Intern Med . 2001; 134 370-379
- 55 Lovell H. Angiotensin converting enzyme inhibitors in normotensive diabetic patients with microalbuminuria. Cochrane Database Syst Rev 2000;CD002183.
- 56 Parving H H, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med . 2001; 345 870-878
- 57 Lewis E J, Hunsicker L G, Clarke W R. Renoprotective effect of the angiotensin-receptor antagonist irbesarten in patients with nephropathy due to type 2 diabetes. N Engl J Med . 2001; 345 851-860
- 58 Brenner B M, Cooper M E, De Zeeuw D. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes nephropathy. N Engl J Med . 2001; 345 861-869
- 59 Chaturvedi N, Sjolie A, Stephenson J. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet . 1998; 351 28-31
- 60 Collins R, Peto R, MacMahon S. Blood pressure, stroke, and coronary heart disease. Lancet . 1990; 335 827-838
- 61 Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med . 1993; 153 143-183
- 62 see below.
Reference Ris Wihthout Link
- 63 Feldman R D, Campbell N, Larochelle P. 1999 Canadian recommendations for the management of hypertension. Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension. Can Med Assoc J . 1999; S1-S17 (S1-S17)
- 64 UKPDS Group. Cost-effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes (UKPDS 40). BMJ . 1998; 317 720-726
- 65 Elliott W, Weir D, Black H. Cost-effectiveness of the lower treatment goal (of JNC VI) for diabetic hypertensive patients. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med . 2000; 160 1277-1283
- 66 Clark W, Churchill D, Forwell L, Macdonald G, Foster S. To pay or not to pay? A decision cost-utility analysis of angiotensin-converting enzyme inhibitor therapy for diabetic nephropathy. Can Med Assoc J . 2000; 162 195-198
- 67 Golan L, Birkmeyer J, Welch H. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med . 1999; 131 660-667
- 68 Pepine C, Handberg-Thurmond E, Marks R. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension. J Am Coll Cardiol . 1998; 32 1228-1237
- 69 Mann J, Julius S. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension, rationale and design. Blood Press . 1998; 7 176-183
- 70 Lauritzen T, Griffin S, Borch-Johnsen K, Wareham N, Wolffenbuttel B, Rutten G. The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with type 2 diabetes detected by screening. Int J Obes Relat Metab Disord . 2000; 6-11 (6-11)
- 71 see below.
Reference Ris Wihthout Link
- 72 Barzilay J, Jones C, Davis B. Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care . 2001; 24 654-658
- 73 Davis B, Cutler J, Gordon D. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens . 1996; 9 342-360
- 74 Pahor M, Psaty B, Alderman M. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet . 2000; 1949-1954
- 75 Pressel S, Davis B, Wright J. Operational aspects of terminating the doxazosin arm of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Control Clin Trials . 2001; 22 29-41
- 76 Sigal R. Cardiovascular disease in diabetes. Clin Evid . 1999; 2 217-230
- 77 see below.
Reference Ris Wihthout Link
- 78 McInnes G. Debate: does it matter how you lower your blood pressure?. Curr Control Trials Cardiovasc Med . 2001; 2 63-66
- 79 Byington R, Furberg C, Craven T, Pahor M, Sowers J. Isradipine in prediabetic hypertensive subjects. Diabetes Care . 1998; 21 2103-2110
- 80 Schwenger V, Ritz E. Audit of antihypertensive treatment in patients with renal failure. Nephrol Dial Transplant . 1998; 13 3091-3095
- 81 Komers R, Komersova K. Therapeutic potential of ACE inhibitors for the treatment of hypertension in Type 2 diabetes. Expert Opin Investig Drugs . 2000; 9 2601-2617
- 82 Agarwal R. Treatment of hypertension in patients with diabetes: lessons from recent trials. Cardiol Rev . 2001; 9 36-44 (ref 62) http://www.diabetesaustralia.com.au/(ref 71) http://www.accordtrial.org/public/purpose.cfm. (ref 77) http://www.nhlbi.nih.gov/meetings/ish/macmahon.htm